TherapeuticsMD (NASDAQ:TXMD)‘s stock had its “buy” rating reiterated by research analysts at Noble Financial in a report released on Thursday, February 22nd.
Other equities research analysts have also recently issued research reports about the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $28.00 price target on shares of TherapeuticsMD in a research note on Sunday, January 7th. BidaskClub raised shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research note on Tuesday, December 12th. Cowen restated an “outperform” rating and issued a $16.00 price objective (up previously from $13.00) on shares of TherapeuticsMD in a report on Monday, November 6th. Oppenheimer restated a “buy” rating and issued a $10.00 price objective on shares of TherapeuticsMD in a report on Sunday, January 28th. Finally, Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Saturday, January 20th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $14.50.
TherapeuticsMD stock traded down $0.09 during mid-day trading on Thursday, hitting $5.10. 1,013,180 shares of the company’s stock traded hands, compared to its average volume of 1,864,798. The stock has a market capitalization of $1,136.10, a price-to-earnings ratio of -13.42 and a beta of 1.36. TherapeuticsMD has a 1-year low of $3.50 and a 1-year high of $8.30.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MANA Advisors LLC acquired a new position in shares of TherapeuticsMD during the fourth quarter worth about $104,000. Paloma Partners Management Co acquired a new position in shares of TherapeuticsMD during the fourth quarter worth about $105,000. Edge Wealth Management LLC grew its position in shares of TherapeuticsMD by 2,500.0% during the fourth quarter. Edge Wealth Management LLC now owns 20,800 shares of the company’s stock worth $125,000 after buying an additional 20,000 shares in the last quarter. Virtu KCG Holdings LLC acquired a new position in shares of TherapeuticsMD during the second quarter worth about $157,000. Finally, Quantbot Technologies LP acquired a new position in shares of TherapeuticsMD during the third quarter worth about $189,000. 73.27% of the stock is owned by institutional investors.
WARNING: This article was first reported by BBNS and is the property of of BBNS. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://baseballnewssource.com/2018/03/20/therapeuticsmds-txmd-buy-rating-reaffirmed-at-noble-financial/1920105.html.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.